PLAT-08: a Study of SC-DARIC33 CAR T Cells in Pediatric and Young Adults with Relapsed or Refractory CD33+ AML

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

January 31, 2041

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse

Interventions

BIOLOGICAL

SC-DARIC33

Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration

Trial Locations (1)

RECRUITING

Seattle Children's Hospital, Seattle

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Seattle Children's Hospital

OTHER